Core Viewpoint - The animal health sector experienced a decline of 0.68% on October 14, with Xianfeng Holdings leading the drop. The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1]. Stock Performance Summary - Zhongmu Co., Ltd. (600195) closed at 7.35, up 1.66% with a trading volume of 120,000 shares and a transaction value of 87.91 million yuan [1]. - Yongshun Biological (920729) closed at 9.31, up 0.54% with a trading volume of 13,800 shares and a transaction value of 12.82 million yuan [1]. - Biological Co. (600201) closed at 10.60, up 0.28% with a trading volume of 624,200 shares and a transaction value of 672 million yuan [1]. - Other notable stocks include Ruip Bio (300119) down 0.45% and Jinhai Bio (002688) down 0.98% [1][2]. Capital Flow Analysis - The animal health sector saw a net outflow of 8.12 million yuan from institutional investors, while retail investors had a net inflow of 4.61 million yuan [2][3]. - Major stocks like Biological Co. (600201) experienced a net inflow of 62.91 million yuan from institutional investors, while Xianfeng Holdings (002141) saw a net outflow of 9.04 million yuan [3].

Core Insights - The animal health sector experienced a rise of 1.98% on October 10, with Bio-Pharmaceuticals leading the gains [1] - The Shanghai Composite Index closed at 3897.03, down 0.94%, while the Shenzhen Component Index closed at 13355.42, down 2.7% [1] Stock Performance - Bio-Pharmaceuticals (600201) closed at 10.16, up 4.42% with a trading volume of 808,300 shares and a transaction value of 815 million [1] - Other notable performers included: - Houbang Holdings (002141) at 3.85, up 3.77% [1] - Ruipu Biological (300119) at 21.87, up 3.16% [1] - Dayu Biological (920970) at 66.6, up 2.62% [1] - Huisheng Biological (300871) at 21.33, up 2.06% [1] Capital Flow - The animal health sector saw a net inflow of 111 million from institutional investors, while retail investors experienced a net outflow of 96.24 million [2] - The capital flow for key stocks included: - Bio-Pharmaceuticals (600201) with a net inflow of 73.87 million from institutional investors [3] - Huisheng Biological (300871) with a net inflow of 17.64 million from institutional investors [3] - Houbang Holdings (002141) with a net inflow of 16.38 million from institutional investors [3]

Core Insights - The animal health sector experienced a slight increase of 0.01% on October 9, with the leading stock being Driveline [1] - The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1] Stock Performance - Driveline (920275) closed at 9.57, up 1.38%, with a trading volume of 17,600 and a turnover of 11.63 million [1] - Jinhai Biological (002688) closed at 6.77, up 1.20%, with a trading volume of 183,400 and a turnover of 123 million [1] - Biological Shares (600201) closed at 9.73, up 0.93%, with a trading volume of 470,500 [1] - Huisheng Biological (300871) closed at 20.90, up 0.87%, with a trading volume of 41,600 [1] - Other notable stocks include Plai Ke (603566) at 13.82, up 0.58%, and Haili Biological (603718) at 6.81, up 0.15% [1] Capital Flow - The animal health sector saw a net outflow of 53.09 million from institutional investors, while retail investors had a net inflow of 28.12 million [2] - The total net inflow from speculative funds was 24.97 million [2] Individual Stock Capital Flow - Ruipu Biological (300119) had a net inflow of 7.31 million from institutional investors, while it experienced a net outflow of 9.14 million from retail investors [3] - Plai Ke (603566) saw a net inflow of 2.41 million from institutional investors but a net outflow of 6.28 million from retail investors [3] - Other stocks like *ST Green Kang (002868) and Jinhai Biological (002688) experienced significant net outflows from institutional investors [3]

Group 1 - The core point of the article is the announcement by Huisheng Biological regarding the composition of its fourth board of directors, which will consist of 5 members, including 2 non-independent directors, 2 independent directors, and 1 employee representative director [1] - The board has nominated Zhang Weiyuan and Liu Zexiang as candidates for non-independent directors, while Ran Mingdong and Wang Ming are nominated as candidates for independent directors [1]

Core Points - The company Huibei Huisheng Biotechnology Co., Ltd., a subsidiary of Huisheng Bio, has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its new veterinary drug "Yin Qiao Lan Qin Oral Solution" [1] Summary by Category - **Regulatory Approval** - The Ministry of Agriculture and Rural Affairs approved the joint application for the new veterinary drug [1] - The new veterinary drug registration certificate was issued on September 26, 2025 [1]

Core Viewpoint - The company Huisheng Bio (回盛生物) announced the election of Ms. Zhou Jian as the employee representative director of the fourth board of directors [1] Group 1 - The announcement was made on the evening of September 30 [1] - The election of Ms. Zhou Jian reflects the company's commitment to employee representation in its governance structure [1]

Core Viewpoint - Recently, the prices of Tylosin and Tylvalosin raw materials have remained relatively stable, influenced by multiple factors [1] Company Summary - The company,回盛生物, addressed investor inquiries on September 30 regarding the pricing of Tylosin and Tylvalosin raw materials [1]

Core Viewpoint - The animal health sector experienced a rise of 0.98% on September 30, with *ST Lvkang leading the gains, while the overall market indices also showed positive movement [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 3882.78, up 0.52% [1]. - The Shenzhen Component Index closed at 13526.51, up 0.35% [1]. - The animal health sector's individual stock performance is detailed in a table, highlighting various stocks' closing prices and percentage changes [1]. Group 2: Stock Performance - *ST Lvkang (002868) closed at 28.01, with a gain of 3.51% and a trading volume of 16,700 shares, amounting to approximately 46.61 million yuan [1]. - Other notable stocks include: - Biological Shares (600201) at 9.64, up 1.69% with a trading volume of 412,400 shares [1]. - Jinhe Biological (002688) at 6.69, up 1.67% with a trading volume of 150,600 shares [1]. - KQ Bio (688526) at 17.72, up 1.37% with a trading volume of 32,700 shares [1]. Group 3: Capital Flow - The animal health sector saw a net inflow of 3.40 million yuan from institutional investors, while retail investors experienced a net outflow of 28.01 million yuan [2][3]. - The detailed capital flow for individual stocks indicates varying levels of net inflow and outflow among different companies [3]. - For instance, Biological Shares (600201) had a net inflow of approximately 19.60 million yuan from institutional investors, while *ST Lvkang (002868) faced a net outflow of about 6.49 million yuan [3].

格隆汇9月30日丨回盛生物(300871.SZ)公布，根据《兽药管理条例》和《兽药注册办法》的规定，经中 华人民共和国农业农村部审查，批准武汉回盛生物科技股份有限公司子公司湖北回盛生物科技有限公司 与其他单位联合申报的"银翘蓝芩口服液"为新兽药，农业农村部于2025年9月26日核发了《新兽药注册 证书》。 ...

Core Viewpoint - In 2025, Wuhan Huisheng Biotechnology Co., Ltd. and its subsidiary obtained a new veterinary drug registration certificate for "Yinqiao Lianqin Oral Solution," which is effective against respiratory diseases in poultry, particularly those caused by external wind-heat [1] Company Summary - The new veterinary drug is classified as a Class III new veterinary drug with a monitoring period of three years [1] - The drug is specifically designed to treat colds in chickens caused by external wind-heat, addressing the prevalent respiratory diseases in poultry [1] - The successful development of this new drug reflects the company's commitment to innovation and enhances its portfolio of traditional Chinese medicine products [1] Industry Summary - There is a limited availability of compliant, green, and antibiotic-free drugs for poultry respiratory diseases, making this new product significant for the industry [1] - The introduction of this drug aligns with industry development requirements and is expected to improve the company's competitiveness in the market [1] - The product must obtain a veterinary drug approval number before it can be marketed [1]